The company adheres to the core mission of “using life science to care for human health”. Over the past 20 years, it has insisted on innovative drug research and development, highlighted new product features, and has now developed into a high-tech pharmaceutical enterprise integrating R&D, production and marketing. The company's industry is pharmaceutical manufacturing. The company focuses on hemostasis and perioperative period, tumor/immunity, bone metabolism, etc. The company's main products are “Mikajisu” and “Sulin”. Corporate honors include: Beijing G20 Leading Enterprise, Beijing Enterprise Technology Center, National Torch Program, National Intellectual Property Demonstration Enterprise, National Postdoctoral Research Workstation, Beijing Engineering Laboratory's “Zhongguancun High-tech Enterprise Certificate”, successfully passed the Beijing Municipal Enterprise Science and Technology Research and Development Agency and Beijing's “Specialized and New” SME review, and was awarded “Top 100 Innovative Chinese Pharmaceutical Enterprises”, “Beijing Top 100 High-tech Enterprises”, “Beijing Top 100 High-tech Enterprises”, “Beijing Top 100 Professional and New Enterprises”, and “2023 China's Top 100 Biomedical Technology Innovation Value List” “Top 10 Influential Biopharmaceutical Companies”, “Top 100 Small and Medium Private Enterprises in Beijing”, “Beijing Top 100 Private Enterprise Social Responsibility”, “Beijing Miyun District Statistical Integrity Demonstration Enterprise”, etc.
No Data